Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial.

@article{Hirsch2006IntracoronaryIO,
  title={Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial.},
  author={Alexander M. Hirsch and Robin Nijveldt and Pieter A van der Vleuten and Bart J. Biemond and Pieter A. F. M. Doevendans and Albert C. van Rossum and Jan G. P. Tijssen and Felix Zijlstra and Jan J. Piek},
  journal={American heart journal},
  year={2006},
  volume={152 3},
  pages={434-41}
}
BACKGROUND Recently, several preliminary reports have demonstrated that cell transplantation after acute myocardial infarction in humans is safe and leads to better preserved left ventricular function and improved myocardial perfusion and coronary flow reserve. METHODS The HEBE trial is a multicenter, prospective, randomized, 3-arm open trial with blinded… CONTINUE READING